Segui
Nicola Relitti
Nicola Relitti
Research Scientist at IRBM
Email verificata su unisi.it
Titolo
Citata da
Citata da
Anno
Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists
S Federico, L Pozzetti, A Papa, G Carullo, S Gemma, S Butini, ...
Journal of Medicinal Chemistry 63 (22), 13466-13513, 2020
782020
Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking
M Brindisi, S Brogi, N Relitti, A Vallone, S Butini, S Gemma, E Novellino, ...
Scientific reports 5 (1), 9705, 2015
752015
Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas
T Khan, N Relitti, M Brindisi, S Magnano, D Zisterer, S Gemma, S Butini, ...
Medicinal Research Reviews 40 (3), 1002-1060, 2020
712020
Telomerase-based cancer therapeutics: a review on their clinical trials
N Relitti, AP Saraswati, S Federico, T Khan, M Brindisi, D Zisterer, S Brogi, ...
Current Topics in Medicinal Chemistry 20 (6), 433-457, 2020
422020
Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors
AP Saraswati, N Relitti, M Brindisi, S Gemma, D Zisterer, S Butini, ...
Drug Discovery Today 24 (7), 1370-1388, 2019
372019
Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors
G Campiani, C Cavella, JD Osko, M Brindisi, N Relitti, S Brogi, ...
Journal of medicinal chemistry 64 (14), 9960-9988, 2021
302021
Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation
N Relitti, AP Saraswati, G Chemi, M Brindisi, S Brogi, D Herp, ...
European Journal of Medicinal Chemistry 212, 112998, 2021
302021
Spiroindoline-capped selective HDAC6 inhibitors: design, synthesis, structural analysis, and biological evaluation
AP Saraswati, N Relitti, M Brindisi, JD Osko, G Chemi, S Federico, A Grillo, ...
ACS Medicinal Chemistry Letters 11 (11), 2268-2276, 2020
302020
Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents
F Saccoccia, M Brindisi, R Gimmelli, N Relitti, A Guidi, AP Saraswati, ...
ACS Infectious Diseases 6 (1), 100-113, 2019
302019
Enantioselective Synthesis of Thailanstatin A Methyl Ester and Evaluation of in Vitro Splicing Inhibition
AK Ghosh, AM Veitschegger, S Nie, N Relitti, AJ MacRae, MS Jurica
The Journal of organic chemistry 83 (9), 5187-5198, 2018
272018
Enantioselective synthesis of a cyclopropane derivative of spliceostatin A and evaluation of bioactivity
AK Ghosh, GC Reddy, S Kovela, N Relitti, VK Urabe, BE Prichard, ...
Organic letters 20 (22), 7293-7297, 2018
212018
Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies
S Butini, E Gabellieri, M Brindisi, A Casagni, E Guarino, PB Huleatt, ...
Bioorganic & medicinal chemistry letters 23 (1), 85-89, 2013
172013
Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems
A Grillo, G Chemi, S Brogi, M Brindisi, N Relitti, F Fezza, D Fazio, ...
European Journal of Medicinal Chemistry 183, 111674, 2019
152019
Bridged bicyclic 2, 3-dioxabicyclo [3.3. 1] nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe (II)
S D'Alessandro, G Alfano, L Di Cerbo, S Brogi, G Chemi, N Relitti, ...
Bioorganic Chemistry 89, 103020, 2019
152019
Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability
S Federico, T Khan, A Fontana, S Brogi, R Benedetti, F Sarno, G Carullo, ...
European Journal of Medicinal Chemistry 238, 114409, 2022
132022
Selective fatty acid amide hydrolase inhibitors as potential novel antiepileptic agents
A Grillo, F Fezza, G Chemi, R Colangeli, S Brogi, D Fazio, S Federico, ...
ACS Chemical Neuroscience 12 (9), 1716-1736, 2021
132021
Retinitis pigmentosa and retinal degenerations: Deciphering pathways and targets for drug discovery and development
G Carullo, S Federico, N Relitti, S Gemma, S Butini, G Campiani
ACS chemical neuroscience 11 (15), 2173-2191, 2020
132020
A light in the dark: state of the art and perspectives in optogenetics and optopharmacology for restoring vision
G Chemi, M Brindisi, S Brogi, N Relitti, S Butini, S Gemma, G Campiani
Future Medicinal Chemistry 11 (5), 463-487, 2019
82019
Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity
N Relitti, S Federico, L Pozzetti, S Butini, S Lamponi, D Taramelli, ...
European Journal of Medicinal Chemistry 215, 113227, 2021
62021
A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents
S Federico, T Khan, N Relitti, G Chemi, M Brindisi, S Brogi, E Novellino, ...
Tetrahedron letters 59 (51), 4466-4470, 2018
62018
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20